LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.
| Revenue (TTM) | $262.43M |
| Gross Profit (TTM) | $188.60M |
| EBITDA | $83.02M |
| Operating Margin | 29.00% |
| Return on Equity | 16.80% |
| Return on Assets | 7.44% |
| Revenue/Share (TTM) | $11.53 |
| Book Value | $18.38 |
| Price-to-Book | 4.48 |
| Price-to-Sales (TTM) | 7.19 |
| EV/Revenue | 6.47 |
| EV/EBITDA | 16.91 |
| Quarterly Earnings Growth (YoY) | 22.60% |
| Quarterly Revenue Growth (YoY) | 9.60% |
| Shares Outstanding | $22.87M |
| Float | $21.30M |
| % Insiders | 6.51% |
| % Institutions | 103.58% |
Volatility is currently expanding
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
LeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue shortages. Not underlying demand. Organic sales grew 10%, and margins hit record highs. Artegraft, now 21% of sales, is LMAT's largest and fastest-growing product. It is the main factor behind margin expansion and international growth prospects.
BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026.
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
BURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.
CASY, CLS, PNTG and LMAT stand out for strong interest coverage as borrowing costs rise, with solid sales/EPS growth estimates and big one-year gains.
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
BURLINGTON, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in two upcoming investor conferences in June.
LeMaitre (LMAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LMAT and any ticker you trade — then tracks every position and per-strategy win rate.
